dothiepin-hydrochloride and Depressive-Disorder--Major

dothiepin-hydrochloride has been researched along with Depressive-Disorder--Major* in 3 studies

Trials

1 trial(s) available for dothiepin-hydrochloride and Depressive-Disorder--Major

ArticleYear
[Clinical and comparative trial of dosulepin and amitriptyline].
    Annales medico-psychologiques, 1978, Volume: 136, Issue:10

    Topics: Adjustment Disorders; Adolescent; Adult; Aged; Amitriptyline; Anxiety Disorders; Clinical Trials as Topic; Depression; Depressive Disorder, Major; Dibenzothiepins; Dothiepin; Drug Tolerance; Female; Humans; Male; Middle Aged; Motor Activity; Sleep Wake Disorders; Thymus Gland

1978

Other Studies

2 other study(ies) available for dothiepin-hydrochloride and Depressive-Disorder--Major

ArticleYear
Comparison of the antidepressant effects of venlafaxine and dosulepin in a naturalistic setting.
    Nordic journal of psychiatry, 2009, Volume: 63, Issue:4

    The relative efficacy of the various classes of antidepressants has not been established. Observational studies in naturalistic settings are important in evaluating treatment outcomes with antidepressants, since controlled clinical trials include only a minority of patients present in clinical practice. This study sought to evaluate in a naturalistic setting the treatment outcomes of dosulepin and venlafaxine for patients with depressive episodes. At the university hospital in Copenhagen, Denmark, between 1998 and early 2001, the first-line treatment for psychiatric inpatients with depression was dosulepin; after that time, venlafaxine was the first-line medication. We compared the treatment outcomes among inpatients during the respective periods. There was no significant difference in the primary outcome parameters between the two groups. A tendency in favour of dosulepin confirmed by a post-hoc analysis suggested that the failure to achieve significant difference was related to a type 2 error. However, missing data and possible confounders related to the different treatment periods weaken the results. This naturalistic study showed a non-significant trend for poorer treatment outcomes (probably because of an underpowered design) after replacing dosulepin with venlafaxine as first-line drug for depression in a naturalistic inpatient setting.

    Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Denmark; Depressive Disorder, Major; Dothiepin; Drug Therapy, Combination; Female; Humans; Length of Stay; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Venlafaxine Hydrochloride

2009
Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia.
    The Australian and New Zealand journal of psychiatry, 2004, Volume: 38, Issue:6

    To investigate the proportion of patients starting on either selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs) who continued treatment for a period consistent with recommended guidelines for major depression, that is at least 6 months.. Cohort study using a national dispensing claims database involving patients eligible for social security entitlements in Australia. Two 'new user' cohorts were established of patients who were supplied a prescription for either an SSRI (6026) or a TCA (4158) in the first week of April 2000 and who had not received a prescription for any antidepressant in the preceding three months. The main outcome measure was the proportion of patients who were still having any SSRI or TCA prescription, respectively, dispensed between 6 and 8 months after initiation. Additionally, for patients starting on either a leading SSRI (sertraline) or TCA (dothiepin), the proportions of those that remained on these drugs or had changed to other antidepressants were determined. The dispensing data are not linked to reason for prescribing in the national dataset.. 2267 SSRI 'new users' (38%) were still receiving SSRIs 6-8 months later, compared with 1269 (31%) of the 4158 TCA 'new users' (p < 0.001). The difference between the groups occurred early, by the 2-4 month time interval. 1038 (41%) of patients starting on the individual SSRI and 385 (38%) of patients starting on the individual TCA were receiving some type of antidepressant therapy at 6-8 months, with no significant difference (p = 0.6) in the proportions that had changed to another antidepressant.. In 2000, only 40% of patients started on an antidepressant continued to be prescribed some antidepressant therapy 6-8 months later. Patients were more likely to continue on SSRIs as a class than on TCAs and the difference in continuation between these two classes occurred within the first 2 months of therapy. However, patients starting on an individual SSRI or TCA were equally likely to change to another antidepressant.

    Topics: Antidepressive Agents, Tricyclic; Cohort Studies; Depressive Disorder, Major; Dothiepin; Humans; Selective Serotonin Reuptake Inhibitors; Sertraline; Time Factors

2004